S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Buy THIS stock before Taiwan is attacked (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
Modern Day Options Trading For Beginners! (Ad)pixel
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Buy THIS stock before Taiwan is attacked (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
Modern Day Options Trading For Beginners! (Ad)pixel
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Buy THIS stock before Taiwan is attacked (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
Modern Day Options Trading For Beginners! (Ad)pixel
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Buy THIS stock before Taiwan is attacked (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
Modern Day Options Trading For Beginners! (Ad)pixel
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
NASDAQ:BGNE

BeiGene - BGNE Stock Forecast, Price & News

$219.71
+0.69 (+0.32%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$216.78
$220.01
50-Day Range
$215.59
$274.50
52-Week Range
$118.18
$280.62
Volume
160,885 shs
Average Volume
231,929 shs
Market Capitalization
$22.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$292.86

BeiGene MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
33.3% Upside
$292.86 Price Target
Short Interest
Bearish
1.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of BeiGene in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$18.47 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($12.65) to ($8.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

286th out of 1,005 stocks

Pharmaceutical Preparations Industry

128th out of 486 stocks


BGNE stock logo

About BeiGene (NASDAQ:BGNE) Stock

BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
BeiGene (NASDAQ:BGNE) Now Covered by StockNews.com
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
What 5 Analyst Ratings Have To Say About BeiGene
See More Headlines
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Company Calendar

Last Earnings
2/27/2023
Today
3/25/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BGNE
Fax
N/A
Employees
9,200
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$292.86
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$213.00
Forecasted Upside/Downside
+33.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-2,003,810,000.00
Net Margins
-141.86%
Pretax Margin
-138.50%

Debt

Sales & Book Value

Annual Sales
$1.42 billion
Book Value
$42.17 per share

Miscellaneous

Free Float
96,491,000
Market Cap
$22.92 billion
Optionable
Optionable
Beta
0.77

Social Links


Key Executives

  • John V. OylerJohn V. Oyler
    Chairman & Chief Executive Officer
  • Xiao Bin WuXiao Bin Wu
    President & Chief Operating Officer
  • Julia Wang
    Chief Financial & Accounting Officer
  • Christiane Langer
    Senior Vice President-Global Medical Affairs
  • Mark Lanasa
    Chief Medical Officer













BGNE Stock - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BGNE shares.
View BGNE analyst ratings
or view top-rated stocks.

What is BeiGene's stock price forecast for 2023?

6 analysts have issued 1 year price objectives for BeiGene's stock. Their BGNE share price forecasts range from $213.00 to $350.00. On average, they expect the company's share price to reach $292.86 in the next year. This suggests a possible upside of 33.3% from the stock's current price.
View analysts price targets for BGNE
or view top-rated stocks among Wall Street analysts.

How have BGNE shares performed in 2023?

BeiGene's stock was trading at $219.94 at the start of the year. Since then, BGNE shares have decreased by 0.1% and is now trading at $219.71.
View the best growth stocks for 2023 here
.

When is BeiGene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our BGNE earnings forecast
.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) announced its quarterly earnings results on Monday, February, 27th. The company reported ($4.29) earnings per share for the quarter, missing the consensus estimate of ($4.18) by $0.11. The firm had revenue of $380.10 million for the quarter, compared to the consensus estimate of $388.17 million. BeiGene had a negative trailing twelve-month return on equity of 39.72% and a negative net margin of 141.86%. The company's quarterly revenue was up 77.6% on a year-over-year basis. During the same period in the previous year, the business posted ($6.22) earnings per share.

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Who are BeiGene's major shareholders?

BeiGene's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.27%), Price T Rowe Associates Inc. MD (0.44%), Bank of America Corp DE (0.30%), Geode Capital Management LLC (0.24%), Fairmount Funds Management LLC (0.23%) and Morgan Stanley (0.17%). Insiders that own company stock include Amgen Inc, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends
.

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $219.71.

How much money does BeiGene make?

BeiGene (NASDAQ:BGNE) has a market capitalization of $22.92 billion and generates $1.42 billion in revenue each year. The company earns $-2,003,810,000.00 in net income (profit) each year or ($19.48) on an earnings per share basis.

How many employees does BeiGene have?

The company employs 9,200 workers across the globe.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for the company is www.beigene.com. The company can be reached via phone at (345) 949-4123 or via email at ir@beigene.com.

This page (NASDAQ:BGNE) was last updated on 3/26/2023 by MarketBeat.com Staff